Potassium ion channel modulators and uses thereof

Patent metadata

Field	Value
Publication number	US-9675567-B2
Application number	US-201615259064-A
Country	US
Kind code	B2
Filing date	Sep 8, 2016
Priority date	Jul 22, 2008
Publication date	Jun 13, 2017
Grant date	Jun 13, 2017

Abstract

Compounds of formula (I):

and pharmacologically acceptable salts and pro-drugs thereof, wherein the variables are as defined in the specification, are potassium ion channel modulators, making them particularly useful in treating and preventing conditions such as pain, lower urinary tract disorders and the like.

First claim

What is claimed is:

1. A method of enhancing KCNQ2/KCNQ3 voltage-dependent potassium channels, wherein diseases treatable by such enhancement are selected from the group consisting of Lower Urinary Tract Disorders, Gynaecological Pain, Cardiac Arrhythmias, Thromboembolic Events, Cardiovascular Diseases, Gastrointestinal Disorders and Visceral Smooth Muscle Disorders, the method comprising administering to a patient in need thereof an effective amount of a compound of formula (I):

or a pharmaceutically acceptable salt thereof,
wherein:
Ar 1 and Ar 2 are each phenyl;
a is 1;
R 1 is halogen;
b is an integer of from 0 to 3;
R 2 is selected from the group consisting of alkyl having from 1 to 3 carbon atoms, halogen, haloalkyl having from 1 to 3 carbon atoms, alkoxy having from 1 to 3 carbon atoms, haloalkoxy having from 1 to 3 carbon atoms, carboxyl, amino, hydroxyl and cyano, and where b is greater than 1, each substituent R 2 may be the same or different;
V is (CR 3a R 3b ) p CON(R 3b )X, wherein said group is in the 3-(meta) or 4-(para) position with respect to the substituent Z;
W is NR 4a , wherein R 4a is selected from the group consisting of hydrogen, alkyl having from 1 to 3 carbon atoms and phenyl;
X is a substituent selected from the group consisting of hydroxyalkyl having from 1 to 4 carbon atoms, polyalkylene glycol residue of general formula:
HO—[(CR 6a R 6b ) c1 —O—(CR 6c R 6d ) c2 ] c3 —

wherein c1 and c2 are the same or different and each is an integer of from 1 to 3, c3 is an integer of from 1 to 10 and R 6a , R 6b , R 6c and R 6d may be the same or different and each is a hydrogen or an alkyl having from 1 to 4 carbon atoms, alkoxyalkyl comprising an alkyl having from 1 to 4 carbon atoms that is substituted with at least one alkoxy having from 1 to 4 carbon atoms, carboxyalkyl comprising an alkyl having from 1 to 4 carbon atoms that is substituted with at least one carboxy, carboxyalkyl comprising alkyl having from 1 to 4 carbon atoms which are substituted with at least one carboxy and alkoxycarbonylalkyl comprising alkyl having from 1 to 4 carbon atoms which are substituted with at least one alkoxycarbonyl having from 2 to 5 carbon atoms;
Y and Z are each a group of formula (CR 5a R 5b ) n1 wherein each n1 is 0;
R 3a and R 3b are the same or different and each is selected from the group consisting of hydrogen and alkyl; and
p is an integer of from 0 to 2.

2. The method according to claim 1 , wherein V is (CR 3a R 3b ) p CON(R 3b )X, wherein said groups is in the 3-(meta) or 4-(para) position with respect to the substituent Z, wherein p is an integer of 0 or 1, each of R 3a and R 3b is hydrogen, and X is selected from the group consisting of alkyl having 1 or 2 carbon atoms which are substituted with a group selected from hydroxyl groups, methoxy groups, ethoxy groups, carboxy groups, methoxycarbonyl groups and ethoxycarbonyl groups.

3. A compound according to claim 1 or a pharmacologically acceptable salt or prodrug thereof, selected from the group consisting of:
{2-[5-(3,5-dichlorophenylamino)-2-fluorophenyl]-acetylamino}acetic acid;
2-[5-(2,6-dichloro-4-trifluoromethoxy-phenylamino)-2-fluoro-phenyl]-N-(2-hydroxy-ethyl)acetamide;
5-(2,6-dichloro-4-trifluoromethyl-phenylamino)-2-fluoro-N-(2-hydroxy-ethyl)-benzamide;
2-[5-(2,6-dichloro-4-trifluoromethyl-phenylamino)-2-fluoro-phenyl]-N-(2-hydroxy-2-methyl-propyl)acetamide; and
2-[4-(2,6-dichloro-4-trifluoromethoxy-phenylamino)-2-fluoro-phenyl]-N-(2-hydroxy-ethyl)propionamide.

4. The method according to claim 1 , wherein said compound forms a part of a pharmaceutical composition which further comprises a pharmacologically acceptable diluent or carrier.

5. The method according to claim 4 , wherein said pharmaceutical composition further comprises at least one compound selected from the group consisting of muscarinic receptor antagonists, β3 adrenergic receptor agonists, neurokinin K receptor antagonists, vanilloid VR1 agonists, calcium channel α2 δ ligands, potassium channel activators, calcium channel inhibitors, sodium channel blockers, serotonin and norepinephrine reuptake inhibitors (SNRIs), 5-HT antagonists, alpha-1 adrenoceptor antagonists, tricyclic antidepressants, N-methyl-D-aspartate (NMDA) receptor antagonists, cannabinoid receptor agonists, anti-convulsants, aldose reductase inhibitors, opioids, alpha adrenoceptor agonists, P2X receptor antagonists, acid-sensing ion channel modulators, NGF receptor modulators, nicotinic acetylcholine receptor modulators, synaptic vesicle protein 2A ligands and non-steroidal anti-inflammatory drugs (NSAIDs).

Assignees

• Ramot At Tel-Aviv Univ Ltd

Inventors

• Edwards Simon
• KIMBERLEY Ruth Meriel
• Armer Richard Edward
• Khan Mohammed Nawaz

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/06

  Antiarrhythmics · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P35/00

  Antineoplastic agents · CPC title